SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through poster presentation at the 2024 European Society for Medical Oncology (ESMO 2024).
This Phase I, open-label, dose-escalation and expansion study was conducted in China to assess the safety and efficacy of MVR-T3011 administered intravesically in patients with high-risk BCG-failure NMIBC. The study enrolled a broader patient population, including those with high-grade Ta, T1, or CIS +/- Ta/T1 bladder cancer, regardless of the presence of CIS. This inclusive approach aims to target a wider range of patients, potentially accelerating future trial enrollment and expanding market opportunities. The treatment was delivered via intravesical instillation at three dose levels, with weekly induction course lasting 12 weeks, followed by bi-weekly maintenance course for up to one year.
According to poster presented (cut-off as of June 27, 2024), among 14 evaluable patients, the overall 3-month complete response (CR) rate across all dose levels was 71.4% (10/14). At the 2×109 PFU dose level (expected RP2D), the CR rate reached an impressive 87.5% (7/8). The study showed a favorable safety profile, with no dose-limiting toxicities (DLTs) reported and no maximum tolerated dose (MTD) reached. Additionally, MVR-T3011 treatment simplifies clinical procedure by eliminating the need for bladder prewash by nature, further reducing patient discomfort. The instillation process is both quick and efficient.
By September 15, 2024, the most recent data shows that 20 subjects have received MVR-T3011 treatment. At the RP2D dose level, the 3-month CR rate remained strong at 81.8% (9/11). Of the 9 patients who have reached the 6-month assessment, 8 have maintained CR, while 4 patients have reached the 9-month assessment and all remained in CR. We are continuing to gather additional data to support further analysis.
"There is a significant unmet need for innovative treatments for bladder cancer," said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. "We are highly encouraged by the preliminary safety and efficacy data from this Phase I study, especially the 3-month CR rate over 80%, along with durable responses at 6- and 9-month time points. With this early success, we are committed to accelerating clinical development of intravesical MVR-T3011 treatments for BCG-failure NMIBC patients and exploring its potential across other bladder cancer indications. Our goal is to provide a novel, effective, and well-tolerated treatment solution for patients."
About MVR-T3011
MVR-T3011, ImmVira's proprietary 3-in-1 oHSV, is a novel genetic engineered oHSV with advanced backbone design aiming to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells and highly restricted replication in normal cells, supporting intratumoral, intravenous and intravesical administrations. Additionally, MVR-T3011 incorporated two latest and well-validated exogenous genes, PD-1 antibody and IL-12, to further enhance immune responses in the tumor microenvironment.
About ImmVira
ImmVira is a biotechnology company focused on developing and synthesizing biological vector delivery platform. The company has constructed a fully integrated OVPENS® (Open Vector+ Potent, Enabling, Novel & Safe) platform with solid science, technology and CMC know-how, and three derivative subplatforms including Oncolytic Virus, Cancer Vaccine and Biosynthetic Exosome, to support ongoing R&D, clinical studies and commercialization of best-in-class mono and combo therapies driven by clinical benefits in oncology and non-oncology fields.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
SYDNEY, Sept. 18, 2024 /PRNewswire/ -- Leading multi-asset broker, Vantage Markets (or "Vantage"), marks its 15th anniversary today, celebrating 15 years of innovating the ultimate* trading machine. Like a well-trained race engineering team, Vantage has spent the last 15 years building and refining its powerful, intuitive trading platforms that integrate cutting-edge technology, to meet the evolving needs of traders worldwide.
To commemorate this milestone, Vantage has unveiled a new gold anniversary logo, symbolising the trust, security and reliability that have defined its journey. From now until the end of the year, clients can look forward to a line-up of exclusive interviews, thrilling videos, and other exciting updates.
Since its incorporation, Vantage has achieved significant milestones that have shaped its growth. The rebranding from VantageFX to Vantage in 2021 marked a pivotal shift, expanding beyond forex to include CFDs on Indices, Shares, Commodities, ETFs, and Bonds. This strategic evolution laid the groundwork for Vantage's rise as a leading multi-asset broker.
In 2022, Vantage entered the world of motorsport sponsorship with NEOM McLaren Extreme E, highlighting the company's commitment to sustainability and innovation. In the media landscape, the partnership with Bloomberg Media Studios to create "The Vantage View" video series further cemented Vantage's role as a thought leader in financial market trends and intelligence.
Vantage's dedication to enhancing user experience is evident through its integration with TradingView and the recent refresh of its website. Beyond trading, Vantage has also made significant contributions to corporate social responsibility, including supporting UNESCO's education initiatives and making a $100,000 donation to the UNHCR for refugee programs in Australia.
Jack Kelly, Head of Sales at Vantage Australia, says, "We're pleased to celebrate this significant milestone. Our 15 year journey has been absolutely remarkable, with a legacy of innovation, growth, excellence and impact. I am looking forward to our exciting next chapter, and will absolutely be bringing our clients along with us for the ride."
Learn more about Vantage's 15 year journey here.
About Vantage
Vantage Markets (or Vantage) is a multi-asset broker offering clients access to a nimble and powerful service for trading Forex and Contracts for Difference (CFDs) products on, Commodities, Indices, Shares, ETFs, and Bonds.
With over 15 years of market experience, Vantage transcends the role of broker, providing a trusted trading ecosystem, an award-winning mobile trading app, and a user-friendly trading platform that empowers clients to seize trading opportunities. Download the Vantage App on App Store or Google Play.
trade smarter @vantage
Vantage Global Prime Pty Ltd (ACN 157 768 566) ("Vantage"), located at 12/15 Castlereagh Street, Sydney, NSW, Australia, 2000, and is authorised and regulated by the Australian Securities & Investments Commission (ASIC) AFSL no. 428901.
Trading derivatives carries significant risks. It is not suitable for all investors and if you are a professional client, you could lose substantially more than your initial investment. When acquiring our derivative products, you have no entitlement, right or obligation to the underlying financial assets. Past performance is no indication of future performance and tax laws are subject to change. The information on this website is general in nature and doesn't take into account your personal objectives, financial circumstances, or needs. Accordingly, before acting on the advice, you should consider whether the advice is suitable for you having regard to your objectives, financial situation and needs. We encourage you to seek independent advice if necessary.
You should consider whether you're part of our target market by reviewing our Target Market Determination (TMD), reading our Product Disclosure Statement (PDS), and other legal documents to ensure you fully understand the risks before you make any trading decisions. We encourage you to seek independent advice if necessary.
*Disclaimer: 'The Ultimate Trading Machine' is a marketing term and does not imply guaranteed performance.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Vantage Australia celebrates its 15 year-journey defined by strategic partnership and innovation
Vantage Australia celebrates its 15 year-journey defined by strategic partnership and innovation
Vantage Australia celebrates its 15 year-journey defined by strategic partnership and innovation
